I've only been here since 2011 this share has risen before because someone said we had a deal with astrazeneca,then that poster who ramped and ramped this share and it rose for no reason......got deleted then came back under another name ....they all rose for a reason SO WHY HAS IT RISEN NOW THEN DAAAAAM
take off your sunglasses something is brewing news will come in a week then the floodgates will open IM SURE
Just be re-reading earlier RNS from Feb this year. This bit got me thinking a bit:
Auto-immune diseases and inflammatory disorders - TYK2+JAK1
Our auto-immune diseases programme is conducted in collaboration with SRI International (SRI), following the agreement announced in April 2013. The disease biology expertise at SRI has focused on disease models that demonstrate how programme compounds are able to block TYK2 dependent signalling.
Steady progress has been made since our last update. In a psoriasis disease model established at SRI, oral administration of the lead molecules leads to a significant reduction in the scaling and redness associated with the disease. Furthermore, the levels of many of the cytokines (signalling molecules) and other proteins thought to be responsible for the symptoms of psoriasis, were shown to be reduced by the addition of programme compounds. In a "rapid efficacy" model also established at SRI, levels of interferon-gamma, a cytokine involved in a number of autoimmune and inflammatory diseases, were shown to be reduced following oral administration of our lead compounds. This model allows us to rapidly screen compounds for biological activity before progressing them into more resource-intensive disease models.
These studies have also indicated that certain of our lead compounds are producing this effect via a combination of TYK2 and JAK1 inhibition. JAK1, like TYK2, is another member of the JAK family of kinases, and is essential for signalling by a number of cytokines also involved in psoriasis, as well as inflammatory bowel disease and rheumatoid arthritis. Our compounds will be tested on models of these diseases in due course. Research into JAK1 has been the subject of considerable scientific interest of late and has resulted in several valuable clinical stage licensing deals.
We are planning to publish the results of our studies in scientific literature and present them at conferences during 2014. An additional patent application protecting programme compounds was published in September 2013.
The-Oracle's remark not to be sniffed at- Tim did it before! On a brighter note,the chinese would only need six months to assess if FLT-3 obtained via SAR,has worked in their leukaemic patients or not.They could easily also have been simultaneously testing it against the competitor FLT-3 Inhibitor such as one obtained from Cephalon(USA).I am not sure about their Regulations but convinced that they are far more flexible than those in Europe and the USA.Stach
You all reason as if we haven't been here before. Sareum could rise to 1.50 today and Tim will show his face and say no reason for rise. And this is Sar might I remind people fluctuations are the norm. Until hardcore rns shows up.
Probably already testing on humans, they don't need any approvals from anyone they just do it. Obviously if results are promising which on mice was 100% successful we can expect some positive feed back and then as leaks occur we will see share price spikes. Just my thoughts. Happy to wait.
THE MORE SAREUM DOES AND KEEPS BUSY WITH MEETINGS, CONTACTS, AND NETWORKING ....the better we can dance with the dreams we all want here ..taking action and guessing wrong GUESSES for spikes in share price is still doing good boys so if anyone has any ideas ..please share with the board its all little steps and everything matters.goodluck
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.